| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Lovastatin | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Increased risk of lovastatin adverse effects |
Initiate lovastatin with the lowest starting dose and titrate to clinical effect. Monitor for adverse effects of lovastatin (e.g. myopathy, elevated transaminases). |
|||
| Darunavir HMG-CoA Reductase Inhibitors 939 | Red: Avoid combination | Do not coadminister: Potential for increased levels of lovastatin | Increased risk of lovastatin adverse effects (e.g. myopathy, rhabdomyolysis) |
Not studied |
Not studied (may increase lovastatin levels) |
Contraindicated. Use alternative agents. |
|
| Atazanavir HMG-CoA Reductase Inhibitors 825 | Red: Avoid combination | Do not coadminister: Potential for increased levels of lovastatin | Increased lovastatin effects (eg, myopathy, rhabdomyolysis) |
Contraindicated. Use alternative agents. |
|||
| Elvitegravir HMG-CoA Reductase Inhibitors 191 | Red: Avoid combination | Do not coadminister: Potential for increased levels of lovastatin | Potential for increased lovastatin effects (e.g. myopathy, rhabdomyolysis) |
Contraindicated. Use alternative agents. |
